https://www.contemporarypediatrics.com/view/fda-accepts-slba-for-altuviiio-in-children-with-hemophilia-a
0
0
FDA accepts sLBA for ALTUVIIIO in children with hemophilia A - Contemporary Pediatrics
9/12/23 at 6:57pm
Organization
Contemporarypediatrics.com
Authors
Celeste Krewson Assistant Editor
Details
41 words
Summarize
Health Health Conditions ALTUVIIIO sLBA FDA FVIII Inhibitory Antibody Titer Shows Implications for Response to IST Treatment A - Contemporary Pediatrics Sanofi
A supplemental biologics license application for ALTUVIIIO (Antihemophilic factor; Sanofi) has been accepted by the FDA for use in patients aged 12 years and older with severe hemophilia A.
Create an account or login to join the discussion